Systemic Inflammatory Response Syndrome
A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever >38 degrees C or HYPOTHERMIA <36 degrees C; (2) TACHYCARDIA >90 beat/minute; (3) tachypnea >24 breaths/minute; (4) LEUKOCYTOSIS >12,000 cells/cubic mm or 10% immature forms. While usually related to infection, SIRS can also be associated with noninfectious insults such as TRAUMA; BURNS; or PANCREATITIS. If infection is involved, a patient with SIRS is said to have SEPSIS.
Subtype terms (3)
More specific conditions that are subtypes of Systemic Inflammatory Response Syndrome in the MeSH hierarchy.
- Cytokine Release Syndrome
52 drugs (37 approved, 15 experimental)
- Sepsis
339 drugs (208 approved, 131 experimental)
- Shock, Septic
163 drugs (112 approved, 51 experimental)
Drugs by status
Phase 4 trials (12)
Phase 3 trials (7)
Phase 2 trials (23)
- metronidazole
- cefazolin
- eritoran
- alanyl-glutaminyl-glycyl-valine
- ifx-1
- piperacillin
- allogeneic hematopoietic stem cells
- gelofusin
- tocilizumab
- ciprofloxacin
- autologous regulatory t cells
- umbilical cord mesenchymal stem cells
- donor regulatory t lymphocytes
- dexmedetomidine
- azithromycin
- neostigmine
- meropenem
- raceanisodamine
- sodium bicarbonate
- sodium chloride
- tazobactam
- cm4620
- cm-4620
Organizations
Organization Involved with Phase 4 Indications (17)
- Fresenius
- AstraZeneca
- ZonMw: The Netherlands Organisation for Health Research and Development
- Region Skane
- Ain Shams University
- McMaster University
- Assiut University
- University of Copenhagen
- University of Vienna
- University of Amsterdam
- Free University of Amsterdam
- University of Strasbourg
- Ludwig Maximilians University
- University of Greifswald
- Canadian Institutes of Health Research (CIHR)
- Tergooi Hospital
- Ono Pharmaceuticals
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (23)
- Eisai
- Athersys, Inc
- InflaRx GmbH
- National Institute of Allergy and Infectious Diseases (NIAID)
- Canadian Critical Care Trials Group
- University of London
- Melbourne Health
- Memorial Hermann Health System
- Radboud University
- University of Melbourne
- University of Ottawa
- University of Toronto
- Austin Health
- University of California, San Francisco
- Department of Defense
- Friedrich Schiller University
- University of Texas at Houston
- Exponential Biotherapies Inc.
- The Physicians' Services Incorporated Foundation
- People's Liberation Army of China
- Ontario Institute for Regenerative Medicine (OIRM)
- Stem Cell Network
- CalciMedica, Inc.
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (9)